Simon Anderhub
YOU?
Author Swipe
View article: Data from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Data from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
BOS172722 (CCT289346) is a highly potent, selective, and orally bioavailable inhibitor of spindle assembly checkpoint kinase MPS1. BOS172722 treatment alone induces significant sensitization to death, particularly in highly proliferative t…
View article: Supplementary Table S3 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Supplementary Table S3 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
Potency of BOS172722 alone, Paclitaxel alone and in combination in TNBC cell lines.
View article: Supplementary Figure S3 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Supplementary Figure S3 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
In vivo efficacy of BOS172722 in MDA-MB-231 tumour bearing mice.
View article: Supplementary Figure S1 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Supplementary Figure S1 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
Cellular activity of BOS172722
View article: Supplementary Table S2 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Supplementary Table S2 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
TNBC and non-TNBC cell line subtype, cell cycle and SAC characteristics and BOS172722 potency.
View article: Supplementary Figure S4 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Supplementary Figure S4 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
Chromosome alignment errors, time course and synergy volume in cells treated with BOS172722 and Paclitaxel.
View article: Supplementary Table S1 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Supplementary Table S1 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
Horizon PTEN +/- cell line panel and Enrichment of mutated genes in cell lines sensitive to BOS172722
View article: Supplementary Figure S1 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Supplementary Figure S1 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
Cellular activity of BOS172722
View article: Supplementary Figure S4 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Supplementary Figure S4 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
Chromosome alignment errors, time course and synergy volume in cells treated with BOS172722 and Paclitaxel.
View article: Supplementary Figure S2 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Supplementary Figure S2 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
Cellular activity of BOS172722 in correlation to tissue of origin, MPS1 mRNA expression and doubling time
View article: Supplementary Figure S2 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Supplementary Figure S2 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
Cellular activity of BOS172722 in correlation to tissue of origin, MPS1 mRNA expression and doubling time
View article: Supplementary Table S1 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Supplementary Table S1 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
Horizon PTEN +/- cell line panel and Enrichment of mutated genes in cell lines sensitive to BOS172722
View article: Data from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Data from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
BOS172722 (CCT289346) is a highly potent, selective, and orally bioavailable inhibitor of spindle assembly checkpoint kinase MPS1. BOS172722 treatment alone induces significant sensitization to death, particularly in highly proliferative t…
View article: Supplementary Table S3 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Supplementary Table S3 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
Potency of BOS172722 alone, Paclitaxel alone and in combination in TNBC cell lines.
View article: Supplementary Table S2 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Supplementary Table S2 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
TNBC and non-TNBC cell line subtype, cell cycle and SAC characteristics and BOS172722 potency.
View article: Supplementary Figure S3 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
Supplementary Figure S3 from High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers Open
In vivo efficacy of BOS172722 in MDA-MB-231 tumour bearing mice.
View article: Supplementary Figure 1 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 1 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 60K, GF-15 does not induce spindle multipolarity in resistant cells
View article: Supplementary Figure Legends 1-5 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure Legends 1-5 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 50K
View article: Supplementary Figure Legends 1-5 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure Legends 1-5 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 50K
View article: Supplementary Figure 4 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 4 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 69K, GF-15 decreases tumor growth in a HT29 xenograft mouse model
View article: Data from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Data from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
In contrast to normal cells, malignant cells are frequently aneuploid and contain multiple centrosomes. To allow for bipolar mitotic division, supernumerary centrosomes are clustered into two functional spindle poles in many cancer cells. …
View article: Supplementary Figure 5 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 5 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 51K, GF-15 significantly increases the mitotic index in MM xenograft tumors
View article: Supplementary Figure 1 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 1 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 60K, GF-15 does not induce spindle multipolarity in resistant cells
View article: Supplementary Figure 3 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 3 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 81K, HeLa-PLK4 cells treated with GF-15
View article: Data from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Data from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
In contrast to normal cells, malignant cells are frequently aneuploid and contain multiple centrosomes. To allow for bipolar mitotic division, supernumerary centrosomes are clustered into two functional spindle poles in many cancer cells. …
View article: Supplementary Figure 3 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 3 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 81K, HeLa-PLK4 cells treated with GF-15
View article: Supplementary Figure 2 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 2 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 239K, HeLa-PLK4 cells display centrosome amplification
View article: Supplementary Figure 5 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 5 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 51K, GF-15 significantly increases the mitotic index in MM xenograft tumors
View article: Supplementary Figure 2 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 2 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 239K, HeLa-PLK4 cells display centrosome amplification
View article: Supplementary Figure 4 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i>
Supplementary Figure 4 from GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth <i>In Vitro</i> and <i>In Vivo</i> Open
PDF file - 69K, GF-15 decreases tumor growth in a HT29 xenograft mouse model